Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA granted Breakthrough Therapy Designation to zoldonrasib for adults with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 therapy and platinum chemotherapy. The designation is based on data from the monotherapy cohort of the Phase 1 RMC-9805-001 trial, which demonstrated encouraging antitumor activity and acceptable safety and tolerability. Zoldonrasib is a tri-complex RAS(ON) G12D-selective covalent inhibitor that binds cyclophilin A. This is the first Breakthrough Therapy Designation for an investigational drug specifically targeting RAS G12D in NSCLC and follows prior designations for the company's daraxonrasib and elironrasib.
Revolution Medicines (Nasdaq: RVMD) said CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT.
The presentation will be available via live webcast at the company's investor events page and a replay will be posted on the website for at least 14 days after the live presentation.
Revolution Medicines (NASDAQ:RVMD) announced on Dec 18, 2025 that the first patient was randomized in RASolute 304, a global, open-label Phase 3 trial of daraxonrasib in resectable pancreatic ductal adenocarcinoma (PDAC) after surgery and perioperative chemotherapy.
RASolute 304 plans to enroll approximately 500 patients with oncogenic RAS mutations and will evaluate whether daraxonrasib improves disease-free survival versus observation; secondary endpoints include overall survival, safety, and tolerability. Daraxonrasib is being evaluated in four global Phase 3 trials, including three in PDAC and one in RAS mutant non-small cell lung cancer.
Revolution Medicines (Nasdaq: RVMD) reported Q3 2025 financial results and clinical progress on RAS(ON) inhibitors.
Clinical: RASolute 302 enrollment for daraxonrasib in previously treated PDAC is winding down with an expected data readout in 2026; RASolute 303 (first-line metastatic PDAC) remains on track to start in 2025; RASolute 304 (adjuvant resectable PDAC) has been initiated. Daraxonrasib holds FDA Breakthrough Therapy, Orphan Drug designation and a Commissioner’s National Priority Voucher. New trials for zoldonrasib, elironrasib and RMC-5127 are planned in 2026–2026 Q1.
Financial: Cash and marketable securities were $1.93B at Sept 30, 2025, including a $250M royalty tranche and $1.75B committed; Q3 R&D $262.5M, G&A $52.8M, net loss $305.2M; reiterated FY2025 GAAP net loss guidance of $1.03B–$1.09B. Company announced senior commercial and development hires and held a webcast on Nov 5, 2025.
Revolution Medicines (Nasdaq: RVMD) announced that CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in two investor conference fireside chats in November 2025.
Event details: Guggenheim Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET, and Jefferies Global Healthcare Conference fireside chat on Tuesday, November 18, 2025 at 9:30 a.m. GMT. Live webcasts and archived replays will be available at the company investor events page, with replay access for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) will report third-quarter 2025 financial results on Wednesday, November 5, 2025 after market close.
The company said a senior management webcast will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. Investors can listen live or access the archived webcast at https://ir.revmed.com/events-and-presentations. A replay will be available on the company website for at least 14 days following the live event.
Revolution Medicines (NASDAQ: RVMD) announced on October 27, 2025 that the U.S. FDA granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer.
Daraxonrasib is a RAS(ON) multi-selective inhibitor currently being studied in a global Phase 3 RASolute 302 trial for second-line metastatic pancreatic ductal adenocarcinoma (PDAC). The company also plans two additional Phase 3 trials: one for first-line metastatic PDAC and one for adjuvant treatment in resectable PDAC.
The designation makes daraxonrasib eligible for incentives, including tax credits for clinical trial costs, exemption from certain FDA fees, and up to seven years of market exclusivity if approved.
Revolution Medicines (Nasdaq: RVMD) reported updated clinical results for elironrasib in previously treated KRAS G12C NSCLC patients who had received prior KRAS(OFF) G12C inhibitors, highlighted at the AACR-NCI-EORTC Symposium (Oct 23-25, 2025).
As of the Aug 4, 2025 cutoff (n=24), elironrasib at 200 mg BID showed a confirmed objective response rate 42% (95% CI: 22-63), disease control rate 79%, median duration of response 11.2 months, median PFS 6.2 months, and 12-month OS rate 62%. In July 2025 elironrasib received Breakthrough Therapy Designation for certain KRAS G12C NSCLC patients.
Revolution Medicines (Nasdaq: RVMD) announced the U.S. FDA granted a non-transferrable Commissioner's National Priority Voucher (CNPV) for daraxonrasib (RMC-6236), its RAS(ON) multi-selective inhibitor.
Daraxonrasib is in two global Phase 3 trials: RASolute 302 (previously treated metastatic pancreatic ductal adenocarcinoma) and RASolve 301 (previously treated metastatic non-small cell lung cancer). The company noted a expected data readout from RASolute 302 in 2026 and said it is evaluating the voucher's impact without changing previously disclosed timelines.
Revolution Medicines (NASDAQ:RVMD), a late-stage clinical oncology company, has announced significant leadership appointments to strengthen its development and commercial capabilities. Dr. Alan Sandler joins as Chief Development Officer, bringing extensive oncology expertise from his previous roles at ALX Oncology, Mirati Therapeutics, and Genentech.
The company has also appointed Alicia Gardner as SVP and General Manager for the U.S. region and Gerwin Winter as SVP and General Manager for Europe. These appointments align with Revolution Medicines' preparation for potential approvals and commercial launches of daraxonrasib for RAS-driven cancers, including pancreatic ductal adenocarcinoma.